Consultant Pathologist BC Cancer Agency
Medical Lead Anatomical Pathology
Medical Director Cervical Cancer Screening Laboratory
Medical Director Clinical Trials, BCCA Laboratories
Clinical Professor of Pathology, University of British Columbia
Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and served as the residency program director for the Anatomic Pathology Residency Program between 2009 – 2017.
Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 60 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) and CAMP pathology Oncology Digital Series (CAMP-PODS) course director.
Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy and fundraising campaigns, being Medical Advisor for Lung Cancer Canada, moderator, presenter and community excellence awardee at ROMPOST TV on Omni TV, and in 2015 supporting biomarker testing before the House of Commons Committee on Health.
Medical Director, Molecular Diagnostics
Medical Director of Research, Division of Anatomical Pathology
Co-chair, Molecular Oncology Diagnostic Testing Provincial Stewardship Committee
Nova Scotia Health
Dr. Carter completed medical school at the University of Toronto, followed by residency training in Anatomical Pathology at Dalhousie University and a 1-year fellowship in Molecular Genetic Pathology at the University of Michigan in Ann Arbor, MI. He began as an Anatomical and Molecular Pathologist at NSH Central Zone and Assistant Professor of Pathology at Dalhousie University in 2018 and, in July 2021, was appointed Medical Director of Molecular Diagnostics at NSH. He is also Medical Director of Research, Division of Anatomical Pathology, and co-chair of the Molecular Oncology Diagnostic Testing Provincial Stewardship Committee for NSH.
Clinical Associate Professor, University of British Columbia
Medical Oncologist, BC Cancer – Vancouver Cancer Centre
Chair of the Provincial Head and Neck Tumour Group, BC Cancer
Dr. Nicole Chau is a Medical Oncologist in Vancouver at BC Cancer and Clinical Associate Professor at the University of British Columbia. She specializes in the care of patients with head and neck cancer and currently serves as Chair of the Provincial Head and Neck Tumour Group at BC Cancer. Dr. Chau obtained her medical degree from the University of Toronto. She completed her residency in Internal Medicine and Medical Oncology at the University of Toronto, and a fellowship in drug development at Princess Margaret Hospital in Toronto and the Dana Farber Cancer Institute in Boston. Prior to joining BC Cancer, Dr. Chau worked as a medical oncologist at the Dana Farber Cancer Institute and Brigham and Women’s Hospital in Boston MA, where she was Assistant Professor of Medicine at Harvard Medical School, specializing in Head and Neck Oncology and Early Drug Development. She has led multiple investigator initiated trials and translational research projects.
Molecular and Anatomical Pathologist
University of Alberta
Dr. Soufiane El Hallani is a Molecular & Anatomical Pathologist and an Assistant Professor at the University of Alberta (Edmonton, Alberta, Canada). His journey started in Marrakech (Morocco) where he completed the M.D. degree. Driven by his passion for genetics, he completed a Master’s in Human Genetics and a Ph.D. in Oncology and Cancer Biology from the University of Paris (France). Motivated by the translation of research knowledge to the clinical side, he joined the residency program in Anatomical Pathology at the University of Ottawa (Canada), then completed the Molecular & Genetic Pathology fellowship at the University of Pittsburgh Medical Centre and the Gynecologic Pathology fellowship at Stanford University (USA). In addition to his clinical duties in Alberta Precision Labs (APL), he is the North R&D Lead of the Molecular Pathology program in APL and Chair of the Somatic Solid Tumor Working group of the Molecular Pathology Discipline Council in Alberta. Dr. El Hallani is a strong advocate for the integration of genomics in the modern practice of pathology to achieve Precision Health transformation and improve pathology diagnoses and patient care.
Professor of Medicine, UBC
Medical Oncologist, BC Cancer - Vancouver
Chair, GI Disease Site, Canadian Cancer Trials Group
President, Canadian Association of Medical Oncologists
Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver. She received a Bachelors of Science in Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 120 peer-reviewed publications and book chapters to her credit. Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and Chair of the UBC Department of Medicine Mentoring Committee. She is the Editor-in-Chief for Current Oncology and is the President of the Canadian Association of Medical Oncologists. Her TEDx talk in 2022 on ‘How to Flip the Script on Cancer’ delivered her passion for patient advocacy and empowerment.
Department of Laboratory Medicine and Pathobiology
Faculty of Medicine
University of Toronto
Dr. Goswami obtained her undergraduate degrees in Genetics and Medical Microbiology from the University of Manitoba and her undergraduate medical degree from the University of Toronto. She subsequently completed her residency in Anatomical Pathology at McGill University and completed a PhD from the University of Toronto examining the use of microRNAs in the prognostication of mantle cell lymphoma. She went on to obtain clinical subspecialty training in Hematopathology and Molecular Genetic Pathology at the University of British Columbia and the MD Anderson Cancer Center, holding U.S. board certification in both subspecialties. Dr. Goswami is an Assistant Professor in the Department of Laboratory Medicine and Pathobiology within the Faculty of Medicine at the University of Toronto. Her primary research interest involves the application of molecular techniques to assist in the diagnosis and prognosis of hematologic and solid tumour malignancies. She is also interested in molecular pathology education and served as the elected Hematopathology representative on the AMP Training & Education from 2017-2019. She currently works as a staff hematopathologist and is the Hematopathology Molecular Lead at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. She is also the current chair of the national working group for the Royal College of Physicians and Surgeons of Canada Area of Focused Competency in Molecular Diagnostics.
Assistant Professor, University of British Columbia
Gynecologic Oncologist, Vancouver General Hospital
Dr. Amy Jamieson is an Assistant Professor at the University of British Columbia and a Gynecologic Oncologist at Vancouver General Hospital and BC Cancer. She completed her obstetrics and gynecology residency at the University of Otago and her gynecologic oncology fellowship at the University of Sydney. She was the first recipient of the Miller-Mindell Translational Research Fellowship with OVCARE/UBC. Her research is focused on molecular stratification of endometrial and vulvar cancers.
Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.
Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.
She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.
Hematologist and Clinician-Scientist
Clinical Director, Centre for Lymphoid Cancer
David Scott is a hematologist and clinician-scientist at BC Cancer in Vancouver, Canada, where he is also the Clinical Director of the Centre for Lymphoid Cancer. His laboratory focusses on the classification of aggressive B-cell lymphoma, mechanisms of treatment resistance and development of diagnostic assays that can be deployed on routine pathology biopsies. His research is currently funded by the NIH (P01), the Lymphoma Research Foundation, Genome Canada, The Terry Fox Research Institute and Michael Smith Health Research Foundation. He is a scientific advisory board member for the Lymphoma Research Foundation, a member of the Lymphoma/Leukemia Molecular Profiling Project and Lunenburg Lymphoma Biomarker Consortium and the translational co-chair of the lymphoma committee for ECOG.
Medical director of immunohistochemistry and molecular pathology
Physician lead of research
William Osler Health System
Brandon Sheffield is an anatomic and molecular pathologist with the William Osler Health System in Canada. He is currently serving as head of the division of advanced diagnostics and the physician lead of research. Dr. Sheffield's main clinical and research interests are in the delivery of laboratory-based personalized medicine, with a focus on making biomarker testing available and accessible for patients in a community practice setting.
Director, Lymphoma Pathology
Head of Department, Pathology & Laboratory Medicine
Pathologist, BC Cancer
Graham Slack is a pathologist at BC Cancer in Vancouver specializing in the pathology of lymphomas. At BC Cancer he serves as the Director of Lymphoma Pathology and Head of the Department of Pathology & Laboratory Medicine. He is an active member in BC Cancer’s Centre for Lymphoid Cancers and a participating member of the Lymphoma/Leukemia Molecular Profiling Project. He is a clinical associate professor in the Department of Pathology and Laboratory Medicine at UBC.
Clinical Associate Professor of Pathology
Associate Director, Molecular Pathology Laboratory
Co-Director of the Genetic Testing Optimization Service,
Stanford University Medical Center
Dr. Suarez is a board-certified pathologist specializing in molecular genetic pathology. He received his M.D. degree from the University of the Valley, Cali, Colombia, where he is originally from. After medical school, he worked as a research fellow at a WHO-collaborating center investigating patterns of nosocomial antibiotic resistance, and later joined the University of California at San Diego (UCSD) as a postdoctoral research fellow in cancer and lung immunology. He completed his anatomic and clinical pathology residency at the University of Washington in Seattle, and his Molecular Genetic Pathology fellowship at Stanford University. Currently, Dr. Suarez is Clinical Associate Professor of Pathology at Stanford University, and he is also Associate Director of the Molecular Pathology Laboratory as well as Co-Director of the Genetic Testing Optimization Service at the Stanford University Medical Center. In addition, he has been a member of the Stanford University Molecular Tumor Board since 2014.
Onco-proteomics lab, head
Department of Pathology
Hadassah Medical Center
Dr. Gilad W. Vainer is a Senior Staff Pathologist, who heads the thoracic pathology unit, and the Onco-proteomics Lab at the Hadassah Medical Center in Jerusalem, Israel. He received his M.D. and Ph.D. in Molecular Biology at the Hebrew University in Jerusalem (2007).
Dr. Vainer is a world leader in molecular pathology and a valued speaker. In recent years, Dr. Vainer gave many several high-profile lectures at different global meetings and conferences, such as the ESMO.
At 2016, Dr. Vainer published the first harmonization of PDL1 (22C3 assay), generating one of the most commonly used protocols globally. He continued to educate about PDL1 testing and quality assurance, both locally and internationally. In 2019-2022, Dr. Vainer presented and advised the Israeli health basket on the advances and medical need for CGP in numerous solid tumors.
Dr. Vainer is a member of several global and regional advisory boards focusing on pathology, oncology, and molecular pathology diagnostics. He received numerous competitive grants and is currently an evaluator with several cancer funding organizations, including the ERA-personalized medicine program.
Chief of gastrointestinal, liver and pancreatic pathology
Department of Anatomical Pathology
University of Texas MD Anderson Cancer Center
Dr. Wang received his M.D. from Tongji Medical University in 1987 and his Ph.D. from University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences in 1999. He received his pathology residency training at UT McGovern Medical School from 1999 to 2003 and his fellowship in Selective Surgical Pathology at UT MD Anderson Cancer Center (MDACC) from 2003 to 2004. Dr. Wang joined the Department of Pathology at MDACC in 2004 as an Assistant Professor specialized in gastrointestinal, liver and pancreatic pathology. He was promoted to an Associate Professor in 2009. He is currently a professor with tenure and the Chief of gastrointestinal, liver and pancreatic pathology. He has joint appointments as a professor in Department of Translational Molecular Pathology and in MD Anderson UTHealth Graduate School of Biomedical Sciences.
Dr. Wang is a well-recognized GI Pathologist and a physician scientist in translational research on pancreatic cancer. He has served as principle investigator (PI), pathology core PI/leader, co-PI/co-investigator for more than 50 ongoing or completed research grants, most of which are from NIH/NCI. His laboratory research, currently funded by two NIH/NCI R01 grants, has been focused on many aspects of pancreatic cancer, including protein kinase and phosphatase alterations, novel pathophysiologic mechanisms and development of new biomarkers. He has served as the chair or member for the NIH and DOD study sections. Dr. Wang has published >270 peer-reviewed publications, 21 invited review articles/letters to the editor; and 15 book chapters. He is the editors for 18 prestigious scientific journals, including Modern Pathology and Laboratory Investigation and ad hoc reviewer for more than 40 journals. Dr. Wang was the President of Chinese American Pathologists Association (CAPA) from 2016 to 2017, the member of USCAP Publication Committee and USCAP Young Investigator Award Committee from 2017 to 2020. He is currently the Chair of Education Committee and the Chair of Neoadjuvant Working Group of Pancreatobiliary Pathology Society and the member of CAP Publication Committee. Dr. Wang received many awards, including the Skip Viragh Career Development Award from the American Association for Cancer Research in 2007, the CAPA President Award in 2020 and the CAPA Distinguished Pathologist Award in 2021.